Report date: Nov 6,2024
Conflict count: 361874
Publisher: AME Publishing Company
Title count: 21
Conflict count: 68


==========================================================

Created: 2022-01-12 20:16:46
ConfID: 6408865
CauseID: 1517770511
OtherID: 1485158478
JT: Precision Cancer Medicine
MD: Collier,3,,34,2020,CM227/CM9-LA: evidence supporting ipilimumab-based immunotherapy in the first-line treatment of metastatic NSCLC
DOI: 10.21037/pcm-2020-mnsclc-04(Journal) (6408865-N)
DOI: 10.21037/pcm-2020-02(Journal)
==========================================================

Created: 2022-01-12 20:16:42
ConfID: 6408864
CauseID: 1517770506
OtherID: 1485158478
JT: Precision Cancer Medicine
MD: Griffiths,3,,33,2020,Pembrolizumab monotherapy in the first-line treatment of EGFR/ALK wildtype, PD-L1 tumor proportion score (TPS) 1–49%, advanced non-small cell lung cancer (NSCLC): con: “It takes two to tango”
DOI: 10.21037/pcm-2020-mnsclc-01(Journal) (6408864-N)
DOI: 10.21037/pcm-20-54(Journal)
==========================================================

Created: 2022-01-12 20:16:51
ConfID: 6408866
CauseID: 1517770515
OtherID: 1485158478
JT: Precision Cancer Medicine
MD: Shao,3,,35,2020,Checkpoint inhibitors first in patients with metastatic non-small cell lung cancer harboring BRAFV600E mutation with PD-L1 90%—a debate in a niche population
DOI: 10.21037/pcm-2020-mnsclc-03(Journal) (6408866-N)
DOI: 10.21037/pcm-20-60(Journal)
==========================================================

Created: 2022-01-12 20:16:09
ConfID: 6408857
CauseID: 1517770456
OtherID: 1470853244
JT: Precision Cancer Medicine
MD: Sehgal,3,,17,2020,Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?
DOI: 10.21037/pcm-2020-potb-02(Journal) (6408857-N)
DOI: 10.21037/pcm-20-20(Journal)
==========================================================

Created: 2022-01-12 20:16:18
ConfID: 6408859
CauseID: 1517770464
OtherID: 1478359331
JT: Precision Cancer Medicine
MD: Ghatak,3,,21,2020,Trastuzumab-Pertuzumab resistance in a case of HER2-del16 expressing colorectal cancer—a case report
DOI: 10.21037/pcm-2020-potb-04(Journal) (6408859-N)
DOI: 10.21037/pcm-20-30(Journal)
==========================================================

Created: 2022-01-12 20:16:13
ConfID: 6408858
CauseID: 1517770460
OtherID: 1478359331
JT: Precision Cancer Medicine
MD: Farid,3,,20,2020,A narrative review of salvage therapy in small cell lung cancer
DOI: 10.21037/pcm-2019-nsclc-09(Journal) (6408858-N)
DOI: 10.21037/pcm-20-24(Journal)
==========================================================

Created: 2022-01-12 20:16:27
ConfID: 6408861
CauseID: 1517770473
OtherID: 1485158478
JT: Precision Cancer Medicine
MD: Dy,3,,24,2020,On opposing ideas
DOI: 10.21037/pcm-2020-mnsclc-07(Journal) (6408861-N)
DOI: 10.21037/pcm-2020-01(Journal)
==========================================================

Created: 2022-01-12 20:16:23
ConfID: 6408860
CauseID: 1517770469
OtherID: 1478359331
JT: Precision Cancer Medicine
MD: Dursun,3,,22,2020,Prolonged immune checkpoint inhibitor response of a patient with a RET rearranged non-small cell lung cancer and high tumour mutational burden: case report and review of the literature
DOI: 10.21037/pcm-2020-potb-03(Journal) (6408860-N)
DOI: 10.21037/pcm-20-26(Journal)
==========================================================

Created: 2022-01-12 20:16:37
ConfID: 6408863
CauseID: 1517770493
OtherID: 1485158478
JT: Precision Cancer Medicine
MD: West,3,,32,2020,ADAURA: a definitive answer to the wrong question
DOI: 10.21037/pcm-2020-mnsclc-02(Journal) (6408863-N)
DOI: 10.21037/pcm-20-55(Journal)
==========================================================

Created: 2022-01-12 20:16:32
ConfID: 6408862
CauseID: 1517770483
OtherID: 1485158478
JT: Precision Cancer Medicine
MD: Sholl,3,,26,2020,A narrative review of BRAF alterations in human tumors: diagnostic and predictive implications
DOI: 10.21037/pcm-2019-ppbt-02(Journal) (6408862-N)
DOI: 10.21037/pcm-20-39(Journal)